An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy

Neuromuscular Disorders

Volumn 12, Issue SUPPL., 2002, Pages

  Kinali, Maria ^a   Mercuri, Eugenio ^a   Main, Marion ^b   Muntoni, Francesco ^a   Dubowitz, Victor ^a  

^a Dubowitz Neuromuscular Centre   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Duchenne; Muscular dystrophy; Prednisolone; Steroids; Treatment

Indexed keywords

DYSTROPHIN; PREDNISOLONE;

BODY GROWTH; BODY HEIGHT; BONE DENSITY; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DUCHENNE MUSCULAR DYSTROPHY; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENE DELETION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MALE; MOTOR PERFORMANCE; MUSCLE FUNCTION; MUSCLE LEVEL; MUSCLE STRENGTH; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DEFICIENCY; REMISSION; SIDE EFFECT; TREATMENT OUTCOME;

BODY WEIGHT; BONE DENSITY; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DYSTROPHIN; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0036823601     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(02)00097-4     Document Type: Conference Paper

References (27)

1. Drachman D.B., Toyka K.V., Myer E. Prednisone in Duchenne muscular dystrophy. Lancet. 142:1974;1409-1412.
2. Brooke M.H., Fenichel G.M., Griggs R.C., et al. Clinical investigation of Duchenne muscular dystrophy: Interesting results in a trial of prednisone. Arch Neurol. 44:1987;812-817.
3. DeSilva S., Drachman D.B., Mellits D., et al. Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit. Arch Neurol. 44:1987;818-822.
4. Mendell J.R., Moxley R.T., Griggs R.C., et al. Randomized double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 320:1989;1592-1597. Comment in: N Engl J Med 1989;321:1481-2.
5. Fenichel G.M., Mendell J.R., Moxley R.T. 3rd, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol. 48:1991;575-579.
6. Fenichel G.M., Florence J.M., Pestronk A., et al. Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology. 41:1991;1874-1877.
7. Griggs R.C., Moxley R.T. 3rd, Mendell J.R., et al. Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical investigation of Duchenne Dystrophy Group. Arch Neurol. 48:1991;383-388.
8. Mesa L.E., Dubrovsky A.L., Corderi J., et al. Steroids in Duchenne muscular dystrophy-deflazacort trial. Neuromuscul Disord. 1:1991;261-266.
9. Dubowitz V. Prednisone in Duchenne dystrophy. Neuromuscul Disord. 1:1991;161-163.
10. Sansome A., Royston P., Dubowitz V. Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule. Neuromuscul Disord. 3:1993;567-569.
11. Angelini C., Pegoraro E., Turella E., et al. Deflazacort in Duchenne dystrophy: Study of long-term effect. Muscle Nerve. 17:1994;386-391.
12. Bonifati M.D., Ruzza G., Bonometto P., et al. A multicenter, double-blind, randomized trial, of deflazacort versus Prednisolone in Duchenne muscular dystrophy. Muscle Nerve. 23:2000;1344-1347.
13. Dubowitz V. 75th European Neuromuscular Centre International Workshop: 2nd workshop on the treatment of muscular dystrophy 10-12 December 99 Naarden The Netherlands. Neuromuscul Disord. 10:2000;313-320.
14. Biggar W.D., Gingras M., Fehlings D.L., et al. Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 138:2001;45-50.
15. Dubowitz V. Muscle disorders in childhood. 2nd ed:1995;Saunders, London.
16. Scott O.M., Hyde S.A., Goddard C., et al. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle Nerve. 5:1982;291-301.
17. Dubowitz V., Kinali M., Main M., et al. Remission of clinical signs in early Duchenne Muscular Dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol. 6:2002;153-159.
18. Arahata K., Engel A.G. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 16:1991;193-208.
19. Engel A.G., Biesecker G. Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann Neurol. 12:1982;289-296.
20. Appleyard S.T., Dunn M.J., Dubowitz V., et al. Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy and other neuromuscular disorders. Lancet. i:1985;361-363.
21. Emslie-Smith A.M., Arahata K., Engel A.G. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 20:1989;224-231.
22. Gorospe J.R., Tharp M.D., Hinckley J., et al. role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. J Neurol Sci. 122:1994;44-56.
23. Gorospe J.R., Tharp M., Demitsu T., et al. Dystrophin-deficient myofibers are vulnerable to mast cell granule-induced necrosis. Neuromuscul Disord. 4:1994;325-333.
24. Granchelli J.A., Pollina C., Hudecki M.S. Duchenne-like myopathy in double-mutant mdx mice expressing exaggerated mast cell activity. J Neurol Sci. 131:1995;1-7.
25. Chen Y.W., Zhao P., Borup R., et al. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol. 151:2000;1321-1336.
26. Fisher I., Morgan J., Abraham D., et al. Glucocorticoid-induced changes in the gene expression of dystrophic mouse muscle (abstract). Neuromuscul Disord. 11:2001;663.
27. Dubowitz V. Therapeutic possibilities in muscular dystrophy: the hope versus the hype. Neuromuscul Disord. 12:2002;113-116.